Last updated on September 2016

A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events


Brief description of study

A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

Detailed Study Description

Patients with type 2 diabetes have increased risk of developing cardiovascular complications. Improved control of hyperglycemia or blood pressure reduces the risk of diabetic complications Administration of bexagliflozin, a potent SGLT2 inhibitor, has been shown to be well tolerated and to decrease HbA1c in subjects with type 2 diabetes. Study THR-1442-C-476 is designed to demonstrate that bexagliflozin also improves glucose control in patients at higher risk of cardiovascular events. There may be additional benefits of bexagliflozin of weight loss and reduction of blood pressure.

Clinical Study Identifier: TX145097

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jeffrey D. Wayne, MD

Clinical Trials Research
Lincoln, CA USA
  Connect »